Business
EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions
EssilorLuxottica acquires RetinAI,accelerating transformative AI and data-powered eye health solutions Paris, France (15 October 2025) – EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group’s med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical
About this update from Essilorluxottica Sa
[{"type":"image","alt":"EssilorLuxottica","displaySize":"","headline":null,"caption":"EssilorLuxottica","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/917e4a586fd01b9ae482d2ec9b2b8eb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NyPhKYW6.EAnTgAoI_btNQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/917e4a586fd01b9ae482d2ec9b2b8eb5","width":300,"height":33}},"lazy":false},{"type":"text","content":"EssilorLuxottica acquires RetinAI,accelerating transformative AI and data-powered eye health solutions","length":103,"tagName":"p"},{"type":"text","content":"Paris, France (15 October 2025) – EssilorLuxottica announces the acquisition of Ikerian AG, a health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. This move reinforces the Group’s med-tech journey, adding advanced software powered by machine learning and computer vision. These solutions streamline clinical, research and pharmaceutical workflows, and deliver actionable AI-driven insights that empower healthcare professionals and enhance patient care.","length":513,"tagName":"p"},{"type":"text","content":"RetinAI develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets. Its FDA cleared 510(k) and CE-marked flagship platform, RetinAI Discovery, applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases. At the same time, RetinAI partners with pharmaceutical companies and research organizations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.","length":613,"tagName":"p"},{"type":"text","content":"“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey. RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence. Leveraging its AI-powered analytics, we can turn clinical data into insights that enable faster, more accurate diagnoses and more ...